A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Beta test our new site.

(NLM Technical Bulletin)

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

This study has been withdrawn prior to enrollment.

( Business/Operational issues )

Study NCT01441388 Information provided by Pfizer

First Received on September 23, 2011. Last Updated on December 19, 2011 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Carcinoma, Renal Cell
Glioblastoma
Carcinoma, Hepatocellular

Additional conditions recognized in this trial

Carcinoma

Interventions listed in this trial

Crizotinib plus axitinib
Crizotinib plus sunitinib
Crizotinib plus bevacizumab
Crizotinib plus sorafenib

Additional drug interventions recognized in this trial

Bevacizumab
Sorafenib
Sunitinib

More general drug interventions related to this trial

Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses

Sponsors listed in this trial

Pfizer

Back to top of Main Content